RPL10AC Antibody

What is RPL10A and why is it important for scientific research?

RPL10A (Ribosomal Protein L10a) is a component of the large 60S ribosomal subunit, which plays a crucial role in protein synthesis within cells. It functions as part of the large ribonucleoprotein complex responsible for translating mRNA into proteins . The importance of RPL10A in research stems from its fundamental role in cellular protein synthesis machinery, making it valuable for studies on ribosome biogenesis, protein translation regulation, and cellular stress responses. Additionally, as a highly conserved protein across species, RPL10A serves as an excellent model for evolutionary studies of ribosomal components .

What are the alternative names for RPL10A that appear in scientific literature?

RPL10A is referenced under several alternative names in scientific literature, which researchers should be aware of when conducting comprehensive literature searches:

Understanding these alternative designations is essential when conducting thorough literature reviews to ensure all relevant research on this ribosomal protein is identified .

What applications are RPL10A antibodies suitable for in research settings?

RPL10A antibodies have been validated for multiple research applications, with varying dilution requirements for optimal results:

These applications enable researchers to investigate RPL10A's expression, localization, and interactions in various experimental contexts .

What species reactivity has been confirmed for commercially available RPL10A antibodies?

The species reactivity profile for RPL10A antibodies varies by product:

This cross-reactivity stems from the high conservation of ribosomal proteins across species. When working with species not explicitly tested, preliminary validation experiments are strongly recommended .

How can I optimize western blot protocols for detecting RPL10A in different cell and tissue types?

Optimizing western blot protocols for RPL10A detection requires consideration of several technical factors:

• Protein extraction considerations:

  • Use NETN buffer (150 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl pH 7.5, 0.5% NP-40) with protease inhibitors for cultured cells

  • For tissue samples, include mechanical disruption (homogenization) before lysis

  • Sonication may improve extraction of ribosome-associated proteins

• SDS-PAGE parameters:

  • 12-15% polyacrylamide gels provide optimal resolution for the 25 kDa RPL10A protein

  • Load 20-50 μg total protein depending on expression level in sample type

• Transfer and detection:

  • PVDF membranes with 0.45 μm pore size are suitable for RPL10A detection

  • Primary antibody dilutions: 1:10000 for ab174318, 1:1000-1:4000 for 16681-1-AP

  • Incubation overnight at 4°C generally yields cleaner results than shorter incubations

This methodology has been validated across multiple published studies and provides reliable detection of the 25 kDa RPL10A protein in diverse experimental contexts .

What are the considerations for using RPL10A antibodies in co-immunoprecipitation studies of ribosomal complexes?

Co-immunoprecipitation (Co-IP) of RPL10A requires careful planning to maintain ribosomal complex integrity:

• Buffer composition considerations:

  • Standard IP buffers often disrupt ribosomal complexes

  • Use physiological salt concentrations (150 mM KCl or NaCl) to maintain associations

  • Include magnesium (5-10 mM MgCl₂) to stabilize ribosomal subunits

  • Mild detergents (0.1-0.5% NP-40 or Triton X-100) balance solubilization with complex preservation

• Technical procedure adaptations:

  • Pre-clear lysates thoroughly to reduce non-specific binding

  • Use 0.5-4.0 μg antibody per 1-3 mg of lysate as validated for 16681-1-AP

  • Shorter incubation times (2-4 hours) may better preserve transient interactions

  • Include RNase inhibitors when studying RNA-dependent interactions

• Validation approaches:

  • Confirm ribosomal complex integrity by detecting known RPL10A-interacting proteins

  • Include isotype controls to assess non-specific binding

  • Consider dual IP-western blot and mass spectrometry for comprehensive analysis

This methodology enables researchers to study RPL10A's interactions within ribosomal complexes while minimizing disruption of physiologically relevant associations .

How can RPL10A antibodies be used to investigate ribosome biogenesis defects in disease models?

RPL10A antibodies can provide critical insights into ribosome biogenesis defects through multiple experimental approaches:

• Quantitative analysis of ribosomal protein levels:

  • Western blot analysis using standardized protocols allows detection of altered RPL10A expression

  • Comparative analysis across normal and disease tissues helps identify dysregulation patterns

  • Internal loading controls should not be ribosomal proteins but stable housekeeping proteins

• Cellular compartmentalization studies:

  • Immunofluorescence microscopy using RPL10A antibodies (1:10-1:100 dilution) visualizes subcellular localization

  • Nucleolar accumulation often indicates biogenesis defects

  • Co-staining with nucleolar markers (fibrillarin, nucleolin) provides contextual information

• Ribosomal subunit assembly assessment:

  • Sucrose gradient fractionation followed by western blotting with RPL10A antibodies

  • Altered RPL10A distribution across fractions indicates assembly defects

  • Comparison between control and disease samples reveals pathological changes

This multi-faceted approach has been employed in studies of ribosomopathies and cancer models, where ribosome biogenesis is frequently dysregulated. The high specificity of RPL10A antibodies for their target makes them valuable tools for characterizing these molecular defects .

What methodological approaches can address potential cross-reactivity concerns when using RPL10A antibodies?

Addressing cross-reactivity concerns requires systematic validation approaches:

• Experimental validation strategies:

  • Perform parallel experiments with multiple antibodies targeting different RPL10A epitopes

  • Include genetic controls (RPL10A knockdown/knockout) to confirm signal specificity

  • Peptide competition assays using the immunogen peptide can distinguish specific from non-specific signals

• Technical optimization for improved specificity:

  • Increase antibody dilution (1:5000-1:10000 for western blots) to reduce non-specific binding

  • Optimize blocking conditions (5% BSA often superior to milk for ribosomal proteins)

  • Use more stringent washing protocols to reduce background

• Confirmatory approaches:

  • Correlation of results with orthogonal methods (mass spectrometry, RNA-seq)

  • Species-specific validation when using antibodies across evolutionary boundaries

  • Recombinant protein standards provide positive controls of known molecular weight

These methodological considerations are particularly important when studying tissues or conditions where ribosomal protein expression may be altered, potentially affecting antibody specificity and detection accuracy .

How should I design experiments to accurately quantify changes in RPL10A expression levels?

Designing experiments for accurate RPL10A quantification requires attention to several methodological aspects:

• Sample preparation standardization:

  • Harvest cells at consistent confluence (70-80%) to minimize variation

  • For tissue samples, use consistent anatomical regions to reduce heterogeneity

  • Process all samples simultaneously with identical protocols to minimize batch effects

• Technical approach selection:

  • Western blot: Suitable for semi-quantitative analysis with careful normalization

  • qPCR: Complementary approach for mRNA expression analysis

  • Flow cytometry: Enables single-cell quantification and population analysis

• Quantification methodologies:

  • Use digital image analysis software with defined threshold settings

  • Establish a standard curve with recombinant RPL10A protein for absolute quantification

  • Employ multiple reference genes/proteins for robust normalization

For western blot quantification, the linear dynamic range for RPL10A detection is approximately 5-50 μg total protein with antibody dilutions of 1:1000-1:10000, depending on the specific antibody used. Biological replicates (minimum n=3) and technical replicates are essential for statistical validation of observed differences .

What controls should be included when using RPL10A antibodies for immunofluorescence studies of subcellular localization?

Robust immunofluorescence studies of RPL10A localization require comprehensive controls:

• Antibody specificity controls:

  • Peptide competition controls to confirm epitope specificity

  • Secondary-only controls to assess non-specific binding

  • RPL10A knockdown/knockout samples as negative controls

• Biological reference controls:

  • Co-staining with established subcellular markers:

    • Nucleoli: Fibrillarin or nucleolin

    • Endoplasmic reticulum: Calnexin or PDI

    • Ribosomes: Other ribosomal proteins (e.g., RPL11)

  • Treatment controls that alter expected localization:

    • Cycloheximide (stabilizes polysomes)

    • Puromycin (disassembles polysomes)

    • Actinomycin D (disrupts nucleolar structure)

• Technical methodology controls:

  • Fixation method comparison (4% paraformaldehyde vs. methanol)

  • Permeabilization optimization (0.1-0.5% Triton X-100)

  • Serial antibody dilutions to establish optimal signal-to-noise ratio

These controls enable confident interpretation of RPL10A localization patterns and distinguish genuine biological phenomena from technical artifacts .

How can I interpret contradictory results between different applications using RPL10A antibodies?

Interpreting contradictory results requires systematic analysis of potential variables:

• Technical factors assessment:

  • Epitope accessibility varies between applications

  • Denaturation status affects antibody recognition (native vs. denatured)

  • Fixation/preservation methods alter antigen presentation

• Antibody-specific considerations:

  • Monoclonal antibodies (e.g., ab174318) recognize single epitopes with high specificity but may be sensitive to epitope modifications

  • Polyclonal antibodies (e.g., ab226381, 16681-1-AP) recognize multiple epitopes, providing robustness but potential cross-reactivity

• Resolution framework for contradictory data:

  • Orthogonal validation using alternative techniques

  • Multiple antibody comparison targeting different epitopes

  • Genetic validation approaches (overexpression, knockdown)

  • Assessment of post-translational modifications affecting epitope recognition

This analytical approach helps researchers resolve apparent contradictions between results obtained using different applications or antibodies against RPL10A. For example, if western blot shows strong signal but immunofluorescence is negative, this could reflect fixation-induced epitope masking rather than absence of the target protein .

What are common troubleshooting approaches for weak or absent signal when using RPL10A antibodies?

When encountering weak or absent RPL10A signals, systematic troubleshooting is required:

• Sample preparation assessment:

  • Verify protein extraction efficiency with alternative extraction methods

  • Confirm protein integrity by Ponceau S staining or detection of stable housekeeping proteins

  • Check for protease activity by adding fresh protease inhibitors

• Detection system optimization:

  • Reduce antibody dilution (e.g., from 1:10000 to 1:1000 for western blot)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Enhance signal with sensitive detection systems (ECL Plus, fluorescent secondaries)

• Application-specific considerations:

  • Western blot: Optimize transfer conditions for 25 kDa proteins

  • Immunofluorescence: Test alternative fixation/permeabilization protocols

  • IP: Increase antibody amount (up to 4 μg per reaction)

• Sample-specific factors:

  • Certain treatments may reduce RPL10A expression

  • Some cell types express lower levels of ribosomal proteins

  • Degradation during improper sample storage

This methodical approach helps distinguish between technical failures and genuine biological absence of the target protein, guiding appropriate experimental adjustments .

How can I address non-specific binding issues when using RPL10A antibodies in complex tissue samples?

Non-specific binding in complex tissues requires targeted optimization strategies:

• Blocking protocol enhancement:

  • Extended blocking (2-3 hours at room temperature)

  • Alternative blocking agents (5% BSA, commercial blocking reagents)

  • Addition of 0.1-0.5% Triton X-100 to reduce hydrophobic interactions

• Washing stringency modification:

  • Increase wash buffer volume and duration

  • Add low concentration of detergent (0.05-0.1% Tween-20)

  • Consider high-salt wash steps (250-500 mM NaCl) to disrupt low-affinity interactions

• Antibody incubation optimization:

  • Pre-absorb antibodies with tissue powder from relevant species

  • Increase dilution to reduce polyclonal antibody cross-reactivity

  • Reduce incubation temperature (4°C rather than room temperature)

• Tissue-specific considerations:

  • Certain tissues (brain, liver) have higher background due to endogenous peroxidases or biotin

  • Additional quenching steps may be necessary

  • Consider tissue-specific antigen retrieval optimization

These approaches have proven effective in improving signal specificity across multiple tissue types including human brain tissue, liver tissue, and complex cell populations .

How can RPL10A antibodies be applied in research on ribosome heterogeneity and specialized ribosomes?

RPL10A antibodies serve as valuable tools for investigating ribosome heterogeneity through several methodological approaches:

• Translating ribosome affinity purification (TRAP) applications:

  • RPL10A-based TRAP enables isolation of cell-type-specific ribosomes

  • Combined with RNA-seq, this reveals translational landscapes in specific cell populations

  • Immunoprecipitation using RPL10A antibodies (0.5-4.0 μg per sample) pulls down intact ribosomes

• Differential composition analysis:

  • Western blotting with RPL10A antibodies across sucrose gradient fractions

  • Comparison between cellular conditions reveals alterations in ribosome composition

  • Quantitative analysis of RPL10A:other ribosomal proteins ratios indicates specialized ribosomes

• Spatial organization studies:

  • Immunofluorescence using RPL10A antibodies (1:10-1:100 dilution) visualizes ribosome distribution

  • Co-localization with mRNA markers reveals specialized translation compartments

  • Comparison across developmental stages or disease states identifies dynamic changes

This multi-faceted approach enables researchers to investigate heterogeneous ribosome populations and their specialized functions in different cellular contexts, contributing to our understanding of translational regulation complexity .

What methodological approaches enable investigation of post-translational modifications of RPL10A?

Investigating RPL10A post-translational modifications (PTMs) requires specialized techniques:

• Detection strategies for common RPL10A modifications:

  • Phosphorylation: Phospho-specific antibodies or Phos-tag SDS-PAGE

  • Ubiquitination: Immunoprecipitation under denaturing conditions

  • Methylation: Antibodies against methylated residues or mass spectrometry

• Experimental workflow for PTM characterization:

  • Immunoprecipitation using RPL10A antibodies (optimal amount: 2-4 μg per sample)

  • Subsequent analysis by western blotting with modification-specific antibodies

  • Mass spectrometry validation for unambiguous identification

  • Site-directed mutagenesis to confirm functional impact

• Physiological context considerations:

  • Compare modifications across different cellular states:

    • Cell cycle phases (synchronization protocols)

    • Stress conditions (oxidative stress, nutrient deprivation)

    • Differentiation stages

This methodological approach has revealed important regulatory mechanisms for ribosomal proteins, including RPL10A, and continues to provide insights into translational regulation through post-translational control of ribosome composition and function .

What emerging research areas could benefit from RPL10A antibody applications?

RPL10A antibodies are positioned to contribute significantly to several emerging research areas:

• Spatial transcriptomics and translation:

  • Integration with in situ hybridization techniques

  • Visualization of active translation sites in complex tissues

  • Single-cell resolution of ribosome heterogeneity

• Ribosomopathies and translational medicine:

  • Diagnostic applications for ribosome-related disorders

  • Therapeutic target validation in diseases with disrupted translation

  • Biomarker development for conditions with altered ribosome biogenesis

• Extracellular vesicle research:

  • Characterization of ribosomal components in exosomes

  • Functional studies of intercellular ribosomal protein transfer

  • Diagnostic applications based on circulating ribosomal proteins

These emerging applications highlight the continuing value of well-characterized RPL10A antibodies in expanding our understanding of ribosome biology and its implications for health and disease .

What are the current limitations of available RPL10A antibodies and potential solutions?

Current limitations and potential solutions for RPL10A antibody applications include:

• Epitope accessibility challenges:

  • Current limitation: Some epitopes become inaccessible in certain experimental conditions

  • Solution: Development of antibodies targeting multiple distinct epitopes

  • Benefit: Improved detection across various applications and conditions

• Species cross-reactivity restrictions:

  • Current limitation: Incomplete validation across evolutionary diverse model organisms

  • Solution: Expanded validation in additional species, particularly non-mammalian models

  • Benefit: Enhanced comparative studies across evolutionary boundaries

• Modification-specific detection:

  • Current limitation: Limited availability of antibodies detecting specific RPL10A modifications

  • Solution: Development of modification-specific antibodies (phospho-RPL10A, etc.)

  • Benefit: Improved understanding of RPL10A regulation and function